DT
PT
Subscribe To Print Edition About The Tribune Code Of Ethics Download App Advertise with us Classifieds
search-icon-img
search-icon-img
Advertisement

Israeli startup Kadimastem to merge With NLS Pharmaceutics

Shareholders of the Israeli bio-pharmaceutical startup, Kadimastem Ltd. approved the company's merger with the Swiss bio-pharmaceutical company NLS Limited on Thursday.
  • fb
  • twitter
  • whatsapp
  • whatsapp
Advertisement

Tel Aviv [Israel], February 2 (ANI/TPS): Shareholders of the Israeli bio-pharmaceutical startup, Kadimastem Ltd. approved the company's merger with the Swiss bio-pharmaceutical company NLS Limited on Thursday.

Advertisement

Founded in 2009 and based in Ness Ziona, Kadmimastem is a clinical-stage cell therapy company, developing "off-the-shelf," allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells.

The Zurich-based NLS focuses on the discovery and development of innovative therapies for rare and complex central nervous system disorders. Its shareholders are due to meet to approve the merger. (ANI/TPS)

Advertisement

(The story has come from a syndicated feed and has not been edited by the Tribune Staff.)

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
tlbr_img1 Home tlbr_img2 Classifieds tlbr_img3 Premium tlbr_img4 Videos tlbr_img5 E-Paper